A pancreatic cancer vaccine called mKRAS-VAX triggered a KRAS mutation-targeted immune response in 9...
Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients
A pancreatic cancer vaccine called mKRAS-VAX triggered a KRAS mutation-targeted immune response in 90% of participants in a Johns Hopkins phase 1 trial.
Author: Fox News
Read Original Article